NAMS 241220 22.50C (NAMS241220C22500) Stock Options, News & Quotes

US OptionsDetailed Quotes

NAMS241220C22500

Watchlist

2.80
0.000.00%

15min DelayClose Dec 20 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$4.07 Million in Common Stock
Moomoo NewsDec 20 16:31 ET
Positive Outlook for NewAmsterdam Pharma Driven by Strong Financial Position and Promising Obicetrapib Trial Results
TipRanksDec 20 12:59 ET
NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$4.86 Million in Common Stock
Moomoo NewsDec 16 16:20 ET
Menarini Group Announces Positive Topline Data From Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib With Ezetimibe 10 Mg
PR NewswireDec 16 08:40 ET
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
BenzingaDec 15 10:00 ET
NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$11.74 Million in Common Stock
Moomoo NewsDec 12 16:18 ET

Comments

10xStockPicks

Dec 15 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

103848509

Dec 10 07:21

$NewAmsterdam Pharma (NAMS.US)$ niceerr high fly prolly

Jaguar8

Nov 20 08:16

NEWS

$NewAmsterdam Pharma (NAMS.US)$
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significa...

SkinnyChick

Nov 20 06:18

$NewAmsterdam Pharma (NAMS.US)$ on watch